Neuromedin N is a potent modulator of dopamine D2 receptor agonist binding in rat neostriatal membranes
References (30)
- et al.
Neuromedin N: high-affinity interaction with brain neurotensin receptors and rapid inactivation by brain synaptic peptidases
Eur. J. Pharmacol.
(1986) - et al.
Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin N
Neurochem, Int.
(1988) - et al.
Hypothermic effect of neuromedin N in mice and its potentiation by peptidase inhibitors
Eur. J. Pharmacol.
(1988) Biochemical characterization of the intramembrane interaction between neurotensin and dopamine D2 receptors in the rat brain
Brain Res.
(1991)- et al.
Neurotensin reduces the affinity of dopamine D2 receptors in membranes from post mortem human caudate-putamen
Neurosci. Lett.
(1990) - et al.
Intraventricular injection of neurotensin reduces dopamine D2 agonist binding in rat forebrain and intermediate lobe of the pituitary gland
Relationship to serum hormone levels and nerve terminal coexistence
Brain Res.
(1990) - et al.
Calcium-dependent release of neurotensin and neuromedin N from mouse hypothalamus
Neuropeptides
(1990) - et al.
Specific in vitro and in vivo binding of [3H]raclopride: a potent substituted benzamine drug with high affinity for dopamine D2 receptors in the rat brain
Biochem. Pharmacol.
(1985) - et al.
Protein measurement with the folin phenol reagent
J. Biol. Chem.
(1951) - et al.
Neuromedin N: a novel neurotensin-like peptide identified in porcine spinal cord
Biochem. Biophys. Res. Commun.
(1984)
Different ontogenetic profiles of cells expressing prepro-neurotensin/neuromedin N mRNA in the rat posterior cingulate cortex and the hippocampal formation
Brain Res. Dev.
(1990)
Structure and functional expression of the cloned rat neurotensin receptor
Neuron
(1990)
Neurotensin and cholecystokinin octapeptide act synergistically to control dopamine release and receptor affinity in rat neostriatum
Eur. J. Pharmacol.
(1993)
Neurotensin binding to dopamine
J. Neurochem.
(1990)
Neurotensin in vitro markedly reduces the affinity of subcortical limbic [3H]propylnorapomorphine binding sites
Acta Physiol. Scand.
(1983)
Cited by (15)
Neurotensin enhances glutamatergic EPSCs in VTA neurons by acting on different neurotensin receptors
2015, PeptidesCitation Excerpt :NT1-13 has a greater potency in decreasing the agonist binding affinity at D2 receptors than NT8-13, however the binding affinity of NT8-13 is higher than NT-13 at NTS1 receptors. This indicates the possible involvement of another NT receptor subtype, in addition to NTS 1 in mediating this effect [24,28,29]. At this point we can only speculate about the possibility of an involvement of NTS 2 receptors on Ih−neurons that mediate this action as we observe that there is a significant cell type by dose interaction in Ih− neurons at the highest concentration.
The neurotensin receptor: Is there more than one subtype?
1996, Trends in Pharmacological SciencesNovel treatments schizophrenia: Targeting the neurotensin system
2006, CNS and Neurological Disorders - Drug Targets
- 1
Permanent address: Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, People's Republic of China.
Copyright © 1993 Published by Elsevier Ireland Ltd.